JAMA Network
About The Study: Among metabolic and bariatric surgery (MBS)-eligible patients in a national sample, semaglutide and tirzepatide prescriptions increased dramatically between 2018 and 2025, whereas MBS use rates declined substantially beginning in 2023. Stratification by procedure type and body mass index (BMI) category suggests that recent shifts in MBS use may be more pronounced in certain patient subgroups (e.g., those seeking sleeve gastrectomy or with lower BMIs).
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
